Androgens, estrogens, and metabolic syndrome at midlife

Menopause

Volumn 16, Issue 2, 2009, Pages 226-228

  Shifren, Jan L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GESTAGEN; GLUCOSE; INSULIN; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ABDOMINAL OBESITY; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; EDITORIAL; ESTROGEN THERAPY; GROUPS BY AGE; HEALTH SURVEY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYSTERECTOMY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; RACE DIFFERENCE;

ANDROGENS; ESTROGENS; FEMALE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 67649324981     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181974ffc     Document Type: Editorial

References (16)

1. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
2. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995;311:1193-1196.
3. Guthrie J, Taffe J, Lehert P, Burger H, Dennerstein L. Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 2004; 11:315-322.
4. Rexrode K, Manson J, Lee I-M, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003; 1-8:1688-1693.
5. Sutton-Tyrrell K, Wildman R, Matthews K, et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005;111:1242-1249.
6. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2005;90:4836-4845.
7. Torrens J, Sutton-Tyrrell K, Zhao X, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in mid-life women: SWAN, the Study of Women's Health Across the Nation. Menopause 2009;16:257-264.
8. Janssen I, Powell L, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome. Arch Intern Med 2008;168: 1568-1575.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
10. Rossouw J, Prentice R, Manson J, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
11. Margolis K, Bonds D, Rodabough R, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187.
12. Polderman K, Gooren L, Asscheman H, Bakker A, Heine R. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994;79:265-271.
13. Davis S, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359: 2005-2017.
14. Rocca W, Grossardt B, Andrade M, Malkasian G, Melton L. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-828.
15. Falkeborn M, Schairer C, Naessen T, Persson I. Risk of myocardial infarction after oophorectomy and hysterectomy. J Clin Epidemiol 2000; 53:832-837.
16. Parker W, Broder M, Liu Z, Shoupe D, Farquhar C, Berek J. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106:219-226.